If you are interested in drug development, you may have heard of the term DMPK, which stands for drug metabolism and pharmacokinetics. DMPK is a branch of science that studies how drugs are absorbed, distributed, metabolized, and excreted in the body. DMPK studies are essential for evaluating the safety and efficacy of new drugs before they enter clinical trials.
But what exactly are DMPK studies and how are they conducted? In this article, we will introduce you to the basic concepts and strategies of preclinical DMPK studies, and how they can help you develop new drugs faster and safer.
What are preclinical DMPK studies?
Preclinical DMPK studies are experiments that are performed on animals or in vitro systems before human testing. The main purpose of preclinical DMPK studies is to provide guidance for clinical trials, such as the optimal route of administration, dosage, and potential drug interactions.
Preclinical DMPK studies can be divided into two categories: in vitro and in vivo studies. In vitro studies are experiments that are performed in test tubes, cell cultures, or tissue slices, using enzymes, transporters, or receptors that are involved in drug metabolism and pharmacokinetics. In vitro studies can evaluate the physicochemical properties and metabolic characteristics of drugs, such as solubility, permeability, stability, metabolic pathways, metabolic enzymes, and drug-drug interactions.
In vivo studies are experiments that are performed on living animals, such as mice, rats, dogs, or monkeys, using different routes of administration, such as intravenous, oral, or subcutaneous. In vivo studies can evaluate the absorption, distribution, metabolism, and excretion of drugs in the body, as well as the pharmacokinetic parameters and safety of drugs. Pharmacokinetic parameters are numerical values that describe how drugs behave in the body, such as clearance, half-life, bioavailability, and volume of distribution.
Why are preclinical DMPK studies important?
Preclinical DMPK studies are important for several reasons. First, preclinical DMPK studies can help screen out potential drug candidates that have poor pharmacokinetic properties or high toxicity, which can save time and money in drug development. Second, preclinical DMPK studies can help optimize drug synthesis and formulation, by providing information on the metabolic pathways and stability of drugs, as well as the best delivery systems and dosage forms. Third, preclinical DMPK studies can help predict the pharmacokinetic behavior and safety of drugs in humans, by using mathematical models and animal data, as well as the potential drug interactions with other drugs or food. This can help design clinical trials and reduce the risk of adverse events.
How to conduct preclinical DMPK studies?
Preclinical DMPK studies can be conducted by using various methods and techniques, depending on the stage and purpose of drug development. For example, in the early stage of drug discovery, in vitro ADME (absorption, distribution, metabolism, and excretion) studies can be used to screen out drug candidates that have poor pharmacokinetic properties, such as low solubility, low permeability, high metabolism, or high binding to plasma proteins. In the later stage of drug development, in vivo DMPK studies can be used to evaluate the pharmacokinetic parameters and safety of drugs in animals, as well as the drug interactions with other drugs or food. In addition, PK-PD (pharmacokinetic-pharmacodynamic) studies can be used to correlate the pharmacokinetic parameters of drugs with their pharmacological effects, such as efficacy and toxicity.
Where to find professional preclinical DMPK services?
If you are looking for professional preclinical DMPK services, you may want to consider Prisys Biotechnology, a leading CRO (contract research organization) company that specializes in drug development outsourcing services. Prisys Biotechnology has a comprehensive and advanced DMPK department, with experienced and qualified staff, state-of-the-art facilities, and various animal models and techniques. Prisys Biotechnology can provide you with a wide range of preclinical DMPK services, such as in vitro ADME studies, in vivo DMPK studies, PK-PD modeling studies, phase I clinical pharmacokinetic studies, and bioequivalence (BE) services. Prisys Biotechnology can also provide you with other services, such as large molecule pharmacokinetic studies, novel formulation development, and prodrug design. Prisys Biotechnology can help you develop new drugs faster and safer, and support your clinical trial application (IND).
If you want to learn more about preclinical DMPK studies and Prisys Biotechnology, please visit contact us. Prisys Biotechnology is your reliable partner for drug development.
